RVTY

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) for the fiscal year ended December 28, 2008. PerkinElmer is a leading provider of technology, services, and solutions for diagnostics, academic research, environmental monitoring, and safety/security markets. The company operates through two primary reporting segments: Life and Analytical Sciences and Optoelectronics. Effective for fiscal year 2009, the company announced a strategic realignment into two new segments: Human Health and Environmental Health.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 14% year-over-year, driven by a 15% increase in the Life and Analytical Sciences segment and a 10% increase in Optoelectronics. Growth was attributed to acquisitions (approx. 4% impact) and favorable foreign exchange rates (approx. 2% impact).
• Profitability: While operating income increased by 18%, net income decreased slightly by 4% due to higher interest and other expenses ($45.6 million in 2008 vs. $16.9 million in 2007). The increase in interest expense was primarily due to the settlement of forward interest rate contracts ($17.5 million loss) and higher debt balances related to the ViaCell acquisition.
• Discontinued Operations: The company recorded a net loss of $2.0 million on the disposition of discontinued operations, including the shutdown of ViaCyte and Cellular Therapy Technology businesses ($8.0 million pre-tax loss) and certain instrument businesses ($4.8 million pre-tax loss).
• Acquisitions: Significant acquisitions in 2008 included Pediatrix Screening (Newborn Metabolic Screening) for ~$66.3 million, LabMetrix (~$4.3 million), VaConics (~$3.9 million), and Arnel (~$2.0 million).

Guidance, Outlook, and Risks

Strategic Outlook: Management is prioritizing the new Human Health and Environmental Health segments. The company plans to divest its Photonics and Photoflash businesses (Optoelectronics) and has shut down specific instrument businesses to focus on higher growth opportunities. Capital expenditures for 2009 are expected to be similar to 2008 levels.

Capital Allocation: The company completed a 10 million share repurchase program in Q3 2008 and authorized a new 10 million share program in October 2008. Quarterly dividends of $0.07 per share were maintained.

Risks and Contingencies:

• Legal Proceedings: Ongoing litigation includes a patent infringement suit with Enzo Biochem (status pending summary judgment) and a resolved suit with PharmaStem (patents declared invalid).
• Environmental: The company has accrued $4.0 million for environmental remediation costs.
• Market Risks: Exposure to foreign currency fluctuations (60% of sales are international) and interest rate changes on variable rate debt.
• Intangible Assets: The company holds $1.8 billion in net intangible assets; management concluded no goodwill impairment existed as of year-end.

Investor Verification Checklist

• Segment Realignment: Verify the financial impact and timeline of the transition from the old (Life/Analytical, Optoelectronics) to the new (Human Health, Environmental Health) reporting structure in 2009.
• Discontinued Operations: Confirm the final sale price and timeline for the divestiture of the Photonics and Photoflash businesses.
• Interest Expense Volatility: Review the $17.5 million one-time charge related to the discontinuance of cash flow hedges and its impact on future earnings projections.
• Acquisition Integration: Assess the integration progress and revenue contribution of the Pediatrix Screening acquisition, which was the largest transaction of the year.
• Debt Covenants: Monitor compliance with debt-to-capital ratios in the revolving credit facility and senior notes, particularly given the economic conditions of 2008.